BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3

Benzinga · 17h ago
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.